



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification<sup>6</sup> :</b> <b>A61K 31/00</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 99/61013</b> <b>(43) International Publication Date:</b> 2 December 1999 (02.12.99)
<b>(21) International Application Number:</b> PCT/US99/11363 <b>(22) International Filing Date:</b> 21 May 1999 (21.05.99) <b>(30) Priority Data:</b> 60/086,494 22 May 1998 (22.05.98) US <b>(71) Applicant:</b> AVANIR PHARMACEUTICALS [US/US]; 9393 Towne Centre Drive #200, San Diego, CA 92121 (US). <b>(72) Inventors:</b> SIRCAR, Jagadish; Avanir Pharmaceuticals, 9393 Towne Centre Drive #200, San Diego, CA 92121 (US). RICHARDS, Mark, L.; Avanir Pharmaceuticals, 9393 Towne Centre Drive #200, San Diego, CA 92121 (US). CAMPBELL, Michael, G.; Avanir Pharmaceuticals, 9393 Towne Centre Drive #200, San Diego, CA 92121 (US). MAJOR, Michael, W.; Avanir Pharmaceuticals, 9393 Towne Centre Drive #200, San Diego, CA 92121 (US). <b>(74) Agent:</b> ALTMAN, Daniel, E.; Knobbe, Martens, Olson & Bear, LLP, 16th floor, 620 Newport Center Drive, Newport Beach, CA 92660 (US).		<b>(81) Designated States:</b> AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published.</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> COMPOUNDS HAVING IgE AFFECTING PROPERTIES <b>(57) Abstract</b> <p>The present invention is directed to small molecule inhibitors of the IgE response to allergens which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

## COMPOUNDS HAVING IgE AFFECTING PROPERTIES

### Background of the Invention

5 This invention relates to small molecule inhibitors of the IgE response to allergens that are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic.

10 An estimated 10 million persons in the United States have asthma, about 5% of the population. The estimated cost of asthma in the United States exceeds \$6 billion. About 25% of patients with asthma who seek emergency care require hospitalization, and the largest single direct medical expenditure for asthma has been inpatient hospital services (emergency care), at a cost of greater than \$1.6 billion. The cost for prescription medications, which increased 54% between 1985 and 1990, was close behind at \$1.1 billion (Kelly, *Pharmacotherapy* 12:13S-21S (1997)).

15 According to the National Ambulatory Medical Care Survey, asthma accounts for 1% of all ambulatory care visits, and the disease continues to be a significant cause of missed school days in children. Despite improved understanding of the disease process and better drugs, asthma morbidity and mortality continue to rise in this country and worldwide (U.S. Department of Health and Human Services; 1991, publication no. 91-3042). Thus, asthma constitutes a significant public health problem.

20 The pathophysiologic processes that attend the onset of an asthmatic episode can be broken down into essentially two phases, both marked by bronchoconstriction, that causes wheezing, chest tightness, and dyspnea. The first, early phase asthmatic response is triggered by allergens, irritants, or exercise. Allergens cross-link immunoglobulin E (IgE) molecules bound to receptors on mast cells, causing them to release a number of pre-formed inflammatory mediators, including histamine. Additional triggers include the osmotic changes in airway tissues following exercise or the inhalation of cold, dry air. 25 The second, late phase response that follows is characterized by infiltration of activated eosinophils and other inflammatory cells into airway tissues, epithelial desquamation, and by the presence of highly viscous mucus within the airways. The damage caused by this

inflammatory response leaves the airways "primed" or sensitized, such that smaller triggers are required to elicit subsequent asthma symptoms.

5 A number of drugs are available for the palliative treatment of asthma; however, their efficacies vary markedly. Short-acting  $\beta_2$ -adrenergic agonists, terbutaline and albuterol, long the mainstay of asthma treatment, act primarily during the early phase as bronchodilators. The newer long-acting  $\beta_2$ -agonists, salmeterol and formoterol, may reduce the bronchoconstrictive component of the late response. However, because the  $\beta_2$ -agonists do not possess significant antiinflammatory activity, they have no effect on bronchial hyperreactivity.

10 Numerous other drugs target specific aspects of the early or late asthmatic responses. For example, antihistamines, like loratadine, inhibit early histamine-mediated inflammatory responses. Some of the newer antihistamines, such as azelastine and ketotifen, may have both antiinflammatory and weak bronchodilatory effects, but they currently do not have any established efficacy in asthma treatment. Phosphodiesterase  
15 inhibitors, like theophylline/xanthines, may attenuate late inflammatory responses, but there is no evidence that these compounds decrease bronchial hyperreactivity. Anticholinergics, like ipratropium bromide, which are used in cases of acute asthma to inhibit severe bronchoconstriction, have no effect on early or late phase inflammation, no effect on bronchial hyperreactivity, and therefore, essentially no role in chronic therapy.

20 The corticosteroid drugs, like budesonide, are the most potent antiinflammatory agents. Inflammatory mediator release inhibitors, like cromolyn and nedocromil, act by stabilizing mast cells and thereby inhibiting the late phase inflammatory response to allergen. Thus, cromolyn and nedocromil, as well as the corticosteroids, all reduce bronchial hyperreactivity by minimizing the sensitizing effect of inflammatory damage to  
25 the airways. Unfortunately, these antiinflammatory agents do not produce bronchodilation.

Several new agents have been developed that inhibit specific aspects of asthmatic inflammation. For instance, leukotriene receptor antagonists (ICI-204, 219, accolate), specifically inhibit leukotriene-mediated actions. The leukotrienes have been implicated  
30 in the production of both airway inflammation and bronchoconstriction.


Thus, while numerous drugs are currently available for the treatment of asthma, these compounds are primarily palliative and/or have significant side effects. Consequently, new therapeutic approaches which target the underlying cause rather than the cascade of symptoms would be highly desirable. Asthma and allergy share a common dependence on IgE-mediated events. Indeed, it is known that excess IgE production is the underlying cause of allergies in general and allergic asthma in particular (Duplantier and Cheng, *Ann. Rep. Med. Chem.* 29:73-81 (1994)). Thus, compounds that lower IgE levels may be effective in treating the underlying cause of asthma and allergy.

None of the current therapies eliminate the excess circulating IgE. The hypothesis that lowering plasma IgE may reduce the allergic response, was confirmed by recent clinical results with chimeric anti-IgE antibody, CGP-51901, and recombinant humanized monoclonal antibody, rhuMAB-E25. Indeed, three companies, Tanox Biosystems, Inc., Genentech Inc. and Novartis AG are collaborating in the development of a humanized anti-IgE antibody (BioWorld® Today, February 26, 1997, p. 2) which will treat allergy and asthma by neutralizing excess IgE. Tanox has already successfully tested the anti-IgE antibody, CGP-51901, which reduced the severity and duration of nasal symptoms of allergic rhinitis in a 155-patient Phase II trial (Scrip #2080, Nov 24, 1995, p.26). Genentech recently disclosed positive results from a 536 patient phase-II/III trials of its recombinant humanized monoclonal antibody, rhuMAB-E25 (BioWorld® Today, November 10, 1998, p. 1). The antibody, rhuMAB-E25, administered by injection (highest dose 300 mg every 2 to 4 weeks as needed) provided a 50% reduction in the number of days a patient required additional "rescue" medicines (antihistamines and decongestants), compared to placebo. An NDA filing for this product is projected to be in the year 2000. The positive results from anti-IgE antibody trials suggest that therapeutic strategies aimed at IgE down-regulation may be effective.

#### Summary of the Invention


The present invention discloses several compounds that are active in down-regulating the IgE response to allergens and other provocative stimuli. One compound is

disclosed for use in the treatment of a condition associated with an excess IgE level. The compound has a formula:




wherein  $n$  is 1 to 3 and wherein  $R$  is H, alkyl, aryl, aminoalkyl, alkylaminoalkyl, substituted aryl or hydroxyalkyl.  $X$ ,  $Y$  and  $Z$  are selected independently from the group consisting of H, alkoxy, aryloxy, alkyl, aryl, heteroaryl, hydroxyalkyl, carboxy, amine, alkylamino, cycloalkylamine, morpholine, thiomorpholine, alkoxy carbonyl, hydroxy, cyano, sulfonamide, alkylsulfonamide, substituted aryl, substituted heteroaryl, trifluoromethyl, trifluoromethoxy, nitro, halogen, thioalkyl, sulfoxyalkyl and sulfonylalkyl.

Another compound for use in the treatment of a condition associated with an excess IgE level is disclosed in accordance with the present invention. The compound has a formula:




wherein  $X$  and  $Y$  are independently selected from the group consisting of H, alkyl, alkoxy, alkoxyalkyl, hydroxyalkyl, benzyl, aryl, heteroaryl, hydroxy, carboxy, halogen, trifluoromethyl, trifluoromethoxy, carboxyalkyl, nitro, cyano, alkylsulfonyl, sulfonamide, alkylsulfonamides, amino, alkylamino, morpholine, thiomorpholine, alkylthio, sulfoxyalkyl and sulfonylalkyl.  $R_1$  and  $R_2$  are independently selected from the group consisting of H, alkyl, aryl, heteroaryl, carboxy, carboxyalkyl and carboxyaryl.  $R_3$  is selected from the group consisting of H, alkyl, aryl, CO-alkyl, CO-aryl and CO-heteroaryl.

Another compound for use in the treatment of a condition associated with an excess IgE level is disclosed in accordance with the present invention. The compound has a formula:




wherein  $R_1$  and  $R_2$  are independently selected from the group consisting of H, alkyl, aryl, heteroaryl, carboxy, carboxyalkyl and carboxyaryl.  $R_3$  is selected from the group consisting of H, alkyl, aryl, CO-alkyl, CO-aryl, dialkylaminoalkyl, dialkylaminoalkylcarbonyl, substituted aryl, substituted heteroaryl and CO-heteroaryl, and  $R$  is selected from the group consisting of H, aryl, heteroaryl, substituted aryl and substituted heteroaryl.

Another compound for use in the treatment of a condition associated with an excess IgE level is disclosed in accordance with the present invention. The compound has a formula:



wherein  $X$  and  $Y$  are independently H, halogens, alkyl, alkoxy, alkoxyalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, trifluoromethyl, trifluoromethoxy, cyano, nitro, amino, acylamino or alkylamino.  $R$ ,  $R'$ ,  $R''$  and  $R'''$  are independently H, alkyl, alkoxyalkyl or dialkylaminoalkyl, and  $R''$  and  $R'''$  may independently also be a halogen.


A preferred variation on the cyclopropyl-substituted compound above is illustrated by the formula:



wherein  $Z$  is  $H_2$  or O.  $X$  and  $Y$  are independently selected from the group consisting of H, halogens, alkyl, alkoxy, alkoxyalkyl, aryl, substituted aryl, heteroaryl, substituted


heteroaryl, trifluoromethyl, trifluoromethoxy, cyano, nitro, amino, acylamino and alkylamino.  $R_1$  and  $R_2$  may be selected independently from the group consisting of H, alkyl, alkoxyalkyl, dialkylaminoalkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl.

- 5 A related compound for use in the treatment of a condition associated with an excess IgE level is disclosed in accordance with the present invention. The compound has a formula:



- 10 wherein Z is  $H_2$  or O. X and Y are independently selected from the group consisting of H, halogens, alkyl, alkoxy, alkoxyalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, trifluoromethyl, trifluoromethoxy, cyano, nitro, amino, acylamino and alkylamino.  $R_1$  and  $R_2$  are selected independently from the group consisting of H, alkyl, alkoxyalkyl, dialkylaminoalkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl.

- 15 Another compound for use in the treatment of a condition associated with an excess IgE level is disclosed in accordance with the present invention. The compound has a formula:




- 20 wherein X and Y are selected independently from the group consisting of H, halogens, alkyl, alkoxy, aryl, amino, alkylamino, cycloalkylamino, morpholine, thiomorpholine,




hydroxy, cyano, nitro, carboxy, alkoxycarbonyl, trifluoromethyl and trifluoromethoxy. R, R', R'' and R''' are selected independently from the group consisting of H, alkyl, aryl, cycloalkyl, substituted cycloalkyl, polycycloalkyl, heteroaryl, arylalkyl, dialkylaminoalkyl and hydroxyalkyl.

- 5 Another compound for use in the treatment of a condition associated with an excess IgE level is disclosed in accordance with the present invention. The compound has a formula:



- 10 wherein R is selected from the group consisting of aliphatic, aromatic, heterocyclic, substituted aromatic and substituted heterocyclic. X and Y are independently selected from the group consisting of H, halogen, alkyl, alkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, hydroxy, nitro, trifluoromethyl, trifluoromethoxy and cyano.


- 15 Another compound for use in the treatment of a condition associated with an excess IgE level is disclosed in accordance with the present invention. The compound has a formula:



wherein R<sub>1</sub> is selected from the group consisting of H, halogen, alkoxy, alkyl, nitro, cyano, amino, CF<sub>3</sub>, OCF<sub>3</sub>, and hydroxy. R<sub>2</sub> is selected from the group consisting of H, alkyl and aminoalkyl, R<sub>3</sub> is H or alkyl, and R<sub>4</sub> and R<sub>5</sub> are independently selected from


the group consisting of H, alkyl, aryl, heteroaryl, substituted aryl, substituted heteroaryl, cycloalkyl, aryl, aminocycloalkyl, hydroxyalkyl and substituted aryl.

Another compound for use in the treatment of a condition associated with an excess IgE level is disclosed in accordance with the present invention. The compound has a formula:




wherein R and R' are selected independently from the group consisting of H, methyl, alkyl, aryl and substituted aryl. X, Y and Z are independently selected from the group consisting of H, halogen, alkyl, alkoxy, benzo, fused heterocyclic, CF<sub>3</sub>, OCF<sub>3</sub>, CN, COOH and COOR".

Another compound for use in the treatment of a condition associated with an excess IgE level is disclosed in accordance with the present invention. The compound has a formula:




wherein the heterocyclic ring is selected from the group consisting of pyridines, quinolines, substituted pyridines and substituted quinolines. R and R' are independently selected from the group consisting of H, methyl, alkyl, aryl and substituted aryl.

Another compound for use in the treatment of a condition associated with an excess IgE level is disclosed in accordance with the present invention. The compound has a formula:



wherein X and Y are independently selected from the group consisting of H, halogen, alkyl, alkoxy, aryl, substituted aryl, hydroxy, amino, alkylamino, cycloalkyl, morpholine, thiomorpholine, nitro, cyano, CF<sub>3</sub> and OCF<sub>3</sub>. R is selected from the group consisting of H, CH<sub>3</sub>, C<sub>2</sub>H<sub>5</sub>, C<sub>3</sub>H<sub>7</sub> and C<sub>4</sub>H<sub>9</sub>, and R<sub>1</sub> and R<sub>2</sub> are selected independently from the group consisting of H, methyl, ethyl, butyl, benzyl, substituted benzyl, dialkylaminoalkyl, alkyl, cycloalkyl, substituted cycloalkyl, polycycloalkyl, substituted fused cycloalkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl.

Another compound for use in the treatment of a condition associated with an excess IgE level is disclosed in accordance with the present invention. The compound has a formula:




wherein X and Y are selected independently from the group consisting of H, alkyl, alkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, hydroxy, halogen, NO<sub>2</sub>, CF<sub>3</sub>, OCF<sub>3</sub>, NH<sub>2</sub>, NHR<sub>3</sub>, NR<sub>3</sub>R<sub>4</sub> and CN. Z is O, S, NH, and N-R'. R is selected from the group consisting of H, alkyl, halogen, alkoxy, CF<sub>3</sub> and OCF<sub>3</sub>. R' is selected from the group consisting of H, alkyl, aminoalkyl, and dialkylaminoalkyl, and R<sub>1</sub> and R<sub>2</sub> are independently selected from the group consisting of H, alkyl, aminoalkyl,

dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, oxacycloalkyl and thiocycloalkyl.


Another compound for use in the treatment of a condition associated with an excess IgE level is disclosed in accordance with the present invention. The compound

5 has a formula:



wherein  $R_1$  and  $R_2$  are selected independently from the group consisting of H, alkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl.  $X$  is selected from the group consisting of H, halogen, alkoxy, alkyl,  $CF_3$ ,  $NO_2$ , CN and  $OCF_3$ .  $R_3$  and  $R_4$  are selected independently from the group consisting of H, alkyl, cycloalkyl, oxacycloalkyl and thiocycloalkyl.


Another compound for use in the treatment of a condition associated with an excess IgE level is disclosed in accordance with the present invention. The compound has a formula:



15

where  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$  and  $R_6$  are selected independently from the group consisting of H, alkyl, cycloalkyl, oxacycloalkyl, thiocycloalkyl, aryl, arylalkyl, heteroaryl, heteroalkyl, substituted aryl and substituted heteroaryl.

Another compound for use in the treatment of a condition associated with an excess IgE level is disclosed in accordance with the present invention. The compound has a formula:



5 wherein  $R_1$  and  $R_2$  are independently selected from the group consisting of H, alkyl, aryl, alkylaryl, substituted alkyl, substituted arylalkyl, dialkyl and aminoalkyl.  $R_3$  is selected from the group consisting of H, alkyl, aryl, halogen,  $CF_3$ ,  $OCF_3$ , CN,  $NO_2$ ,  $NH_2$ , NHR, carboxy, carboxyalkyl, alkoxy, heteroaryl, fused aryl and fused heteroaryl.

10 A method for treating a disease condition associated with excess IgE in a mammal is disclosed. The method comprises the step of administering to the mammal an IgE-suppressing amount of a pharmaceutical formulation comprising at least one IgE-suppressing compound from the above-disclosed small molecule families. In accordance with a variation of the method of treatment, the small molecule IgE-suppressing compound may be administered in conjunction with at least one additional agent, which is





15 active in reducing a symptom associated with an allergic reaction. In one embodiment, the small molecule inhibitor may be mixed with at least one additional active ingredient to form a pharmaceutical composition. Alternatively, the small molecule inhibitor may be co-administered at the same time or according to different treatment regimens with the at least one additional active agent.






20 The at least one additional active ingredient may be a short-acting  $\beta_2$ -adrenergic agonist selected from the group consisting of terbutaline and albuterol; a long-acting  $\beta_2$ -adrenergic agonist selected from the group consisting of salmeterol and formoterol; an antihistamine selected from the group consisting of loratadine, azelastine and ketotifen; a





phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor or a leukotriene receptor antagonist.

A dose of about 0.01 mg to about 100 mg per kg body weight per day of the small molecule IgE inhibitory compound is preferably administered in divided doses for at least two consecutive days at regular periodic intervals.


A method for treating a disease condition associated with excess IgE in a mammal is also disclosed which comprises the step of administering to the mammal an IgE-suppressing amount of a pharmaceutical formulation comprising at least one compound selected from the following group of compounds:






























wherein Z is selected from the group consisting of NH, O, S and N-R';

wherein R' is selected from the group consisting of H, alkyl, aminoalkyl,


5 and dialkylaminoalkyl;


wherein R<sub>1</sub> is selected from the group consisting of H, Cl and

SO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>; and

wherein R<sub>2</sub> is selected from the group consisting of H, Cl, CH<sub>3</sub>, OCH<sub>3</sub>,  
COOH and CF<sub>3</sub>,

10





5

Other variations within the scope of the present invention may be more fully understood with reference to the following detailed description.

#### Detailed Description of the Preferred Embodiment

10 The present invention is directed to small molecule inhibitors of IgE (synthesis and/or release) which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic. The particular compounds disclosed herein were identified by

their ability to suppress IgE levels in both *ex vivo* and *in vivo* assays. Development and optimization of clinical treatment regimens can be monitored by those of skill in the art by reference to the *ex vivo* and *in vivo* assays described below.

5     Ex Vivo Assay

          This system begins with *in vivo* antigen priming and measures secondary antibody responses *in vitro*. The basic protocol was documented and optimized for a range of parameters including: antigen dose for priming and time span following priming, number of cells cultured *in vitro*, antigen concentrations for eliciting secondary IgE (and other  
10    Ig's) response *in vitro*, fetal bovine serum (FBS) batch that will permit optimal IgE response *in vitro*, the importance of primed CD4<sup>+</sup> T cells and hapten-specific B cells, and specificity of the ELISA assay for IgE (Marcelletti and Katz, *Cellular Immunology* 135:471-489 (1991); incorporated herein by reference).

          The actual protocol utilized for this project was adapted for a more high  
15    throughput analyses. BALB/cByj mice were immunized i.p. with 10 µg DNP-KLH adsorbed onto 4 mg alum and sacrificed after 15 days. Spleens were excised and homogenized in a tissue grinder, washed twice, and maintained in DMEM supplemented with 10% FBS, 100 U/ml penicillin, 100 µg/ml streptomycin and 0.0005% 2-mercaptoethanol. Spleen cell cultures were established (2-3 million cells/ml, 0.2 ml/well  
20    in quadruplicate, 96-well plates) in the presence or absence of DNP-KLH (10 ng/ml). Test compounds (2 µg/ml and 50 ng/ml) were added to the spleen cell cultures containing antigen and incubated at 37° C for 8 days in an atmosphere of 10% CO<sub>2</sub>.

          Culture supernatants were collected after 8 days and Ig's were measured by a modification of the specific isotype-selective ELISA assay described by Marcelletti and  
25    Katz (*Supra*). The assay was modified to facilitate high throughput. ELISA plates were prepared by coating with DNP-KLH overnight. After blocking with bovine serum albumin (BSA), an aliquot of each culture supernatant was diluted (1:4 in phosphate buffered saline (PBS) with BSA, sodium azide and Tween 20), added to the ELISA plates, and incubated overnight in a humidified box at 4° C. IgE levels were quantitated

following successive incubations with biotinylated-goat antimouse IgE (b-GAME), AP-streptavidin and substrate.

Antigen-specific IgG1 was measured similarly, except that culture supernatants were diluted 200-fold and biotinylated-goat antimouse IgG1 (b-GAMG1) was substituted for b-GAME. IgG2a was measured in ELISA plates that were coated with DNP-KLH following a 1:20 dilution of culture supernatants and incubation with biotinylated-goat antimouse IgG2a (b-GAMG2a). Quantitation of each isotype was determined by comparison to a standard curve. The level of detectability of all antibody was about 200-400 pg/ml and there was less than 0.001% cross-reactivity with any other Ig isotype in the ELISA for IgE.

#### In Vivo Assay

Compounds found to be active in the *ex vivo* assay (above) were further tested for their activity in suppressing IgE responses *in vivo*. Mice receiving low-dose radiation prior to immunization with a carrier exhibited an enhanced IgE response to sensitization with antigen 7 days later. Administration of the test compounds immediately prior to and after antigen sensitization, measured the ability of that drug to suppress the IgE response. The levels of IgE, IgG1 and IgG2a in serum were compared.

Female BALB/cByj mice were irradiated with 250 rads 7 hours after initiation of the daily light cycle. Two hours later, the mice were immunized i.p. with 2  $\mu$ g of KLH in 4 mg alum. Two to seven consecutive days of drug injections were initiated 6 days later on either a once or twice daily basis. Typically, i.p. injections and oral gavages were administered as suspensions (150  $\mu$ l/injection) in saline with 10% ethanol and 0.25% methylcellulose. Each treatment group was composed of 5-6 mice. On the second day of drug administration, 2  $\mu$ g of DNP-KLH was administered i.p. in 4 mg alum, immediately following the morning injection of drug. Mice were bled 7-21 days following DNP-KLH challenge.

Antigen-specific IgE, IgG1 and IgG2a antibodies were measured by ELISA. Periorbital bleeds were centrifuged at 14,000 rpm for 10 min, the supernatants were diluted 5-fold in saline, and centrifuged again. Antibody concentrations of each bleed




were determined by ELISA of four dilutions (in triplicate) and compared to a standard curve: anti-DNP IgE (1:100 to 1:800), anti-DNP IgG2a (1:100 to 1:800), and anti-DNP IgG1 (1:1600 to 1:12800).

## 5 Active Compounds of the Present Invention

The following series of compounds were found to be potent inhibitors of IgE in both *ex-vivo* and *in vivo* models.


One family of small molecule IgE inhibitors in accordance with the present invention include substituted benzanilides, defined by formula I:



I


where n is 1 to 3, R is H, alkyl, aryl, aminoalkyl, alkylaminoalkyl, substituted aryl or hydroxyalkyl, and where X, Y and Z are selected independently from the group consisting of H, alkoxy, aryloxy, alkyl, aryl, heteroaryl, hydroxyalkyl, carboxy, amine, alkylamino, cycloalkylamine, morpholine, thiomorpholine, alkoxycarbonyl, hydroxy, cyano, sulfonamide, alkylsulfonamide, substituted aryl, substituted heteroaryl, trifluoromethyl, trifluoromethoxy, nitro, halogen, thioalkyl, sulfoxyalkyl, sulfonylalkyl or the like.

One compound encompassed within the definition of formula I, which was active in suppressing IgE, is represented by formula I.1:



## I.1

Compounds of formula I can be synthesized by the following reaction:




5

The reactants can be obtained from a commercial supplier, such as Aldrich Chemical Company, catalog numbers T6,980-9 and 19,323-2. Modifications as suggested by formula I can be prepared by conventional reactions, well known in the field.

10

Another family of small molecule IgE inhibitors is defined by generic formula II(1) below.




II(1)

15


wherein X is a cycloalkyl or substituted cycloalkyl having from 4-6 carbons, where R<sub>1</sub> and R<sub>2</sub> are independently H, alkyl, aryl, heteroaryl, carboxy, carboxyalkyl and carboxyaryl, where R<sub>3</sub> is H, alkyl, aryl, CO-alkyl, CO-aryl, dialkylaminoalkyl, dialkylaminoalkylcarbonyl, substituted aryl, substituted heteroaryl and CO-heteroaryl, and where R is H, aryl, heteroaryl, substituted aryl, substituted heteroaryl or the like.

More preferably, the genus is represented by formula II(2).


20




II(2)




V.2




V.3




V.4



V.5




V.6




V.7

Compounds of formula V can be synthesized by any conventional reactions known in the art. The above species V.1-7 were synthesized by the following reaction, where the benzene ring can be substituted, as indicated by the X (e.g., bromide, as in V.2) and the amide is varied to yield the desired compounds:



The reactants were obtained from commercial suppliers, such as Aldrich Chemical Company, catalog number 19,169-8. Modifications can be prepared by conventional reactions, well known in the field.


Another useful class of compounds is represented by the formula VI:




VI

where R is aliphatic, aromatic, heterocyclic, substituted aromatic, substituted heterocyclic or the like, and where X and Y are independently, H, halogen, alkyl, alkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, hydroxy, nitro, trifluoromethyl, trifluoromethoxy, cyano or the like. Replacement of the carboxylic acid with other bioisosteric groups such as tetrazole and tetrazoleamide is also contemplated in accordance with the present invention.


The following compounds encompassed within the family defined by formula VI were prepared and found to be active in suppressing IgE:




VI.1




VI.2




VI.3




VI.4



VI.5




VI.6



VI.7


5           Compounds of formula VI may be synthesized by any conventional reactions known in the art. One example of a synthesis reaction is shown below:



Where the reactants can be obtained from a commercial supplier, such as Aldrich Chemical Company, catalog numbers B460-0 and 10,080-3. Modifications can be prepared by conventional reactions, well known in the field.

10


Other small molecules active in suppressing IgE include those represented by formula VII.



VII


- 5 where  $R_1$  is H, halogen, alkoxy, alkyl, nitro, cyano, amino,  $CF_3$ ,  $OCF_3$  or hydroxy, where  $R_2$  is H, alkyl or aminoalkyl, where  $R_3$  is H or alkyl, and where  $R_4$  and  $R_5$  are independently H, alkyl, aryl, heteroaryl, substituted aryl, substituted heteroaryl, cycloalkyl, aminocycloalkyl, aryl, hydroxyalkyl, substituted aryl or the like.

- 10 The following compounds encompassed within the family defined by formula VII were prepared and found to be active in suppressing IgE:




VII.1







VII.2




VII.3



VII.4




VII.5




VII.6

Compounds of formula VII may be synthesized by any conventional reactions known in the art. The compounds above (VII.1-6) were prepared according to the reaction illustrated below, where X represents the different substitutions on the benzene ring:



The reactants can be obtained from a commercial supplier, such as Aldrich Chemical Company, catalog numbers 19,374-2 and T8,380-1. Modifications can be prepared by conventional reactions, well known in the field.

Other substituted benzene ring molecules contemplated in accordance with the invention are illustrated by formula VIII(1):




VIII(1)

where R and R' are selected independently from the group consisting of H, methyl, alkyl, aryl, substituted aryl, heteroaryl and substituted heteroaryl, and where X, Y and


Z are independently H, halogen, alkyl, alkoxy, benzo, fused heterocyclic,  $\text{CF}_3$ ,  $\text{OCF}_3$ , CN, nitro,  $\text{COOH}$  or  $\text{COOR}$ ".

Compounds encompassed by formula VIII(1) were prepared and found to be active in suppressing IgE; they are represented by formulas VIII.1 and VIII.2:

5




VIII(1).1



VIII(1).2

10

Another useful class of compounds in accordance with the present invention represents a modification of formula VIII(1), by replacement of the benzene ring with a heterocyclic ring. These compounds are represented by formula VIII(2):




VIII(2)

15

where the heterocyclic ring is pyridines, quinolines, substituted pyridines, substituted quinolines or other heterocyclic compounds, and where R and R' are independently H, methyl, alkyl, aryl or substituted aryl.


Compounds of formula VIII may be synthesized by any conventional reactions known in the art. An example of a synthesis reaction is shown below:



Where the reactant can be obtained from a commercial supplier, such as Aldrich Chemical Company, catalog number 12,213-0. Modifications can be prepared by conventional reactions, well known in the field.

5

Another family of compounds active in the suppressing the IgE response are represented by formula IX(1):




IX(1)

- 10 wherein  $\text{X}$  and  $\text{Y}$  are selected independently from the group consisting of H, alkyl, alkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, hydroxy, halogen,  $\text{NO}_2$ ,  $\text{CF}_3$ ,  $\text{OCF}_3$ ,  $\text{NH}_2$ ,  $\text{NHR}_3$ ,  $\text{NR}_3\text{R}_4$  and  $\text{CN}$ .  $\text{Z}$  is O, S, NH, and  $\text{N-R}'$ .  $\text{R}$  is selected from the group consisting of H, alkyl, halogen, alkoxy,  $\text{CF}_3$  and  $\text{OCF}_3$ .  $\text{R}'$  is selected from the group consisting of H, alkyl, aminoalkyl, and dialkylaminoalkyl, and  $\text{R}_1$  and  $\text{R}_2$  are
- 15 independently selected from the group consisting of H, alkyl, aminoalkyl,

dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, oxacycloalkyl and thiocycloalkyl.

Several compounds (IX.1-9) encompassed within the broad family defined by formula IX(1) were prepared and found to be active in suppressing IgE. They are defined by formula IX(2) with X, R<sub>1</sub> and R<sub>2</sub> specified in Table 2:




IX(2)

Table 2

	R <sub>1</sub>	R <sub>2</sub>	X
IX.1	H	5-Cl	NH
IX.2	6-Cl	5-Cl	NH
IX.3	H	5-CH <sub>3</sub>	O
IX.4	5-SO <sub>2</sub> CH <sub>2</sub> CH <sub>3</sub>	H	O
IX.5	H	6-OCH <sub>3</sub>	O
IX.6	H	5-COOH	NH
IX.7	H	6-OCH <sub>3</sub>	O
IX.8	H	4-CH <sub>3</sub>	O
IX.9	H	5-CF <sub>3</sub>	N-CH(CH <sub>3</sub> ) <sub>2</sub>

Compounds of formula IX may be synthesized by any conventional reactions known in the art. An example of a synthesis reaction is shown below:




The reactants can be obtained from a commercial suppliers, such as Molecular Probes Inc., catalog number D-1421 and Aldrich Chemical Company, catalog number 39,898-5. Modifications can be prepared by conventional reactions, well known in the field.

5 Another synthesis that was used successfully to produce 3-(6'-methyl-2'-benzoxazolyl)-7-diethylamino-2H-1-benzo-pyran-2-one ( $\text{R}_1 = \text{H}$ ,  $\text{R}_2 = 6\text{-CH}_3$  and  $\text{X} = \text{O}$ ) involved mixing 7-diethylamino-2-oxo-2H-1benzopyran-3-carboxylic acid (2.5 g, 9.57 mol) [CIBA Ltd., British Patent 914719; Chem Abs. 61 (1964) 3242e; Ayyangar et al., Dyes & Pigments, 13:301-316 (1990)], 2-hydroxy-4-methylaniline (1.18 g, 9.57 mol) and PPA (25 ml). The mixture was stirred at  $180^\circ \text{C}$  for 5.0 hr, then poured into ice-water (400 ml), neutralized with 10% NaOH and 10%  $\text{NaHCO}_3$  to pH 8.5 and extracted with  $\text{CHCl}_3$  (4 x 400 ml). The chloroform extract was dried and treated with charcoal, filtered and concentrated. The residue was recrystallized from hexane and  $\text{CH}_2\text{Cl}_2$  (1:1) to give 1.75 g, m.p.  $189\text{-}191^\circ \text{C}$ .

15 A mixture of 7-diethylamino-2-oxo-2H-1benzopyran-3-carboxylic acid, the appropriate substituted o-aminophenol or o-phenylenediamine and PPA were stirred at  $180^\circ \text{C}$  for several hrs, as detailed above for each of the species IX.1-9.


Another group of compounds active in the suppressing the IgE response are represented below. In particular, substituted 1,3,5-triazine compounds are illustrated in X(1):



X(1)

where  $R_1$  and  $R_2$  are independently H, alkyl, aryl, heteroaryl, arylalkyl or heteroarylalkyl, where X is H, halogen, alkoxy, alkyl,  $CF_3$ ,  $NO_2$ , CN or  $OCF_3$ , and where  $R_3$  and  $R_4$  are independently H, alkyl, cycloalkyl, oxacycloalkyl or thiocycloalkyl.


General modification of the 1,2,3-triazine ring, useful in the present invention is represented by formula X(2):



X(2)


where  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$  and  $R_6$  are the same or different and selected independently from the group consisting of alkyl, cycloalkyl, oxacycloalkyl, thiocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, substituted aryl and substituted heteroaryl.

One compound encompassed by formula X was prepared and found to be active in suppressing IgE; it is represented by formula X.1:



X.1


Compounds of formula X may be synthesized by any conventional reactions known in the art. An example of a synthesis reaction is shown below:



The reactant can be obtained from a commercial suppliers, such as Aldrich Chemical Company, catalog number C9,550-1. Modifications can be prepared by conventional reactions.



Another group of compounds which are active in inhibiting the IgE response in the *ex vivo* and *in vivo* assays is represented by formula XI:



XI

where  $R_1$  and  $R_2$  are independently H, alkyl, aryl, alkylaryl, substituted alkyl, substituted arylalkyl, dialkyl and aminoalkyl, and where  $R_3$  is H, alkyl, aryl, halogen,  $CF_3$ ,  $OCF_3$ , CN,  $NO_2$ ,  $NH_2$ , NHR, carboxy, carboxyalkyl, alkoxy, heteroaryl, fused aryl, fused heteroaryl and the like.

A series of compounds encompassed within the definition of formula XI were synthesized according to the following reaction, where the compounds are defined by the substitutions provided in Table 3.

To a solution of 4-(1-adamantyl)-phenol (10 g, 0.044 mol) in DMF (40 ml) at  $-5^\circ C$  was added to solid sodium hydride (1.8 g, 0.077 mol) and DMF (20 ml). After the evolution of gas ceased, epichlorohydrin was added dropwise with stirring. The reaction mixture was stirred for 48 hr and then poured onto cold water (500 ml), extracted with EtOH (3 x 100 ml), dried, concentrated to give 8.1 g of the desired epoxide. Purity was measured by GC at 94.1%.

The epoxide (1.0 g) was reacted with excess tert-butylamine at  $60^\circ C$  for 24 hr and worked up as described above to give 1.1 g of the desired product, m.p.  $94-96^\circ C$ .

Table 3


	$R_1$	$R_2$
XI.1	H	isopropyl
XI.2	H	2-(2',5'-dimethoxy)-phenylethyl

XI.3


 $R_1 = R_2 = \text{thiomorpholine}$ 

Compounds encompassed by formula XI were prepared and found to be active in suppressing IgE; they is represented by formulas XI.1-4:


5




XI.1



XI.2




XI.3



XI.4

Compounds of formula XI may be synthesized by any conventional reactions known in the art. The above compounds were synthesized according to the reaction illustrated below:



- 5 The reactants can be obtained from a commercial suppliers, such as Aldrich Chemical Company, catalog number 39,347-9. Modifications can be prepared by conventional reactions.

#### Suppression of IgE Response

- 10 The inhibitory activity of the small molecules of the present invention were assayed using both the *ex vivo* and *in vivo* assays as described above. All of the compounds presented above were active in suppressing the IgE response. In the *ex vivo* assay, compounds in genres I-XI produced 50% inhibition at concentrations ranging from 1 pM to 10  $\mu$ M. In the *in vivo* assay, the compounds were effective at concentrations
- 15 ranging from less than about 0.01 mg/kg/day to about 25 mg/kg/day, when administered in divided doses (e.g., two to four times daily) for at least two to seven consecutive days. Thus, the small molecule inhibitors of the present invention are disclosed as being useful in lowering the antigen-induced increase in IgE concentration, and consequently, in the treatment of IgE-dependent processes such as allergies in general and allergic asthma in
- 20 particular.

#### Treatment Regimens

The amount of the IgE inhibitor compound which may be effective in treating a particular allergy or condition will depend on the nature of the disorder, and can be

determined by standard clinical techniques. The precise dose to be employed in a given situation will also depend on the choice of compound and the seriousness of the condition, and should be decided according to the judgment of the practitioner and each patient's circumstances. Appropriate dosages can be determined and adjusted by the practitioner based on dose response relationships between the patient's IgE levels as well as standard indices of pulmonary and hemodynamic changes. Moreover, those skilled in the art will appreciate that dose ranges can be determined without undue experimentation by following the protocol(s) disclosed herein for *ex vivo* and *in vivo* screening (See for example Hasegawa et al., *J. Med. Chem.* 40: 395-407 (1997) and Ohmori et al., *Int. J. Immunopharmacol.* 15:573-579 (1993); employing similar *ex vivo* and *in vivo* assays for determining dose-response relationships for IgE suppression by naphthalene derivatives; incorporated herein by reference).


Initially, suitable dosages of the compounds will generally range from about 0.001 mg to about 300 mg per kg body weight per day in divided doses, more preferably, between about 0.01 mg and 100 mg per kg body weight per day in divided doses. The compounds are preferably administered systemically as pharmaceutical formulations appropriate to such routes as oral, aerosol, intravenous, subcutaneously, or by any other route which may be effective in providing systemic dosing of the active compound. The compositions of pharmaceutical formulations are well known in the art. The treatment regimen preferably involves periodic administration. Moreover, long-term therapy may be indicated where allergic reactions appear to be triggered by continuous exposure to the allergen(s). Daily or twice daily administration has been effective in suppressing the IgE response to a single antigen challenge in animals when carried out continuously from a period of two to seven consecutive days. Thus, in a preferred embodiment, the compound is administered for at least two consecutive days at regular periodic intervals. However, the treatment regimen, including frequency of dosing and duration of treatment may be determined by the skilled practitioner, and modified as needed to provide optimal IgE down-regulation, depending on nature of the allergen, the dose, frequency, and duration of the allergen exposure, and the standard clinical indices.

In one embodiment of the present invention, an IgE-suppressing compound may be administered in conjunction with one or more of the other small molecule inhibitors disclosed, in order to produce optimal down-regulation of the patient's IgE response. Further, it is envisioned that one or more of the compounds of the present invention may be administered in combination with other drugs already known or later discovered for treatment of the underlying cause as well as the acute symptoms of allergy or asthma. Such combination therapies envisioned within the scope of the present invention include mixing of one or more of the small molecule IgE-inhibitors together with one or more additional ingredients, known to be effective in reducing at least one symptom of the disease condition. In a variation, the small molecule IgE-inhibitors herein disclosed may be administered separately from the additional drugs, but during the same course of the disease condition, wherein both the IgE-inhibitor(s) and the palliative compounds are administered in accordance with their independent effective treatment regimens.

While a number of preferred embodiments of the invention and variations thereof have been described in detail, other modifications and methods of use will be readily apparent to those of skill in the art. Accordingly, it should be understood that various applications, modifications and substitutions may be made of equivalents without departing from the spirit of the invention or the scope of the claims.

WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising any one or more of the following compounds:




(A)

wherein n is 1 to 3;

wherein R is H, alkyl, aryl, aminoalkyl, alkylaminoalkyl, substituted aryl or hydroxyalkyl; and

wherein X, Y and Z are selected independently from the group consisting of H, alkoxy, aryloxy, alkyl, aryl, heteroaryl, hydroxyalkyl, carboxy, amine, alkylamino, cycloalkylamine, morpholine, thiomorpholine, alkoxycarbonyl, hydroxy, cyano, alkylsulfonyl, sulfonamide, alkylsulfonamide, substituted aryl, substituted heteroaryl, trifluoromethyl, trifluoromethoxy, nitro, halogen, thioalkyl, sulfoxyalkyl and sulfonylalkyl;




(B)

wherein R<sub>1</sub> and R<sub>2</sub> are independently selected from the group consisting of H, alkyl, aryl, heteroaryl, carboxy, carboxyalkyl and carboxyaryl;

wherein R<sub>3</sub> is selected from the group consisting of H, alkyl, aryl, CO-alkyl, CO-aryl, dialkylaminoalkyl, dialkylaminoalkylcarbonyl, substituted aryl, substituted heteroaryl and CO-heteroaryl; and

wherein R is selected from the group consisting of H, aryl, heteroaryl, substituted aryl and substituted heteroaryl;




(C)

wherein Z is H<sub>2</sub> or O;

wherein X and Y are independently selected from the group consisting of  
 5 H, halogens, alkyl, alkoxy, alkoxyalkyl, aryl, substituted aryl, heteroaryl, substituted  
 heteroaryl, trifluoromethyl, trifluoromethoxy, cyano, nitro, amino, acylamino and  
 alkylamino; and

wherein R<sub>1</sub> and R<sub>2</sub> are independently selected from the group consisting of  
 H, alkyl, alkoxyalkyl, dialkylaminoalkyl, cycloalkyl, substituted cycloalkyl, aryl,  
 10 substituted aryl, heteroaryl, and substituted heteroaryl;




(D)

wherein Z is H<sub>2</sub> or O;

wherein X and Y are independently selected from the group consisting of  
 15 H, halogens, alkyl, alkoxy, alkoxyalkyl, aryl, substituted aryl, heteroaryl, substituted  
 heteroaryl, trifluoromethyl, trifluoromethoxy, cyano, nitro, amino, acylamino and  
 alkylamino; and


wherein R<sub>1</sub> and R<sub>2</sub> are independently selected from the group consisting  
 of H, alkyl, alkoxyalkyl, dialkylaminoalkyl, cycloalkyl, substituted cycloalkyl, aryl,  
 20 substituted aryl, heteroaryl, and substituted heteroaryl;



(E)

wherein X and Y are selected independently from the group consisting of H, halogens, alkyl, alkoxy, aryl, amino, alkylamino, cycloalkylamino, morpholine, thiomorpholine, hydroxy, cyano, nitro, carboxy, alkoxycarbonyl, trifluoromethyl and trifluoromethoxy; and

wherein R, R', R'' and R''' are selected independently from the group consisting of H, alkyl, aryl, cycloalkyl, substituted cycloalkyl, polycycloalkyl, heteroaryl, arylalkyl, dialkylaminoalkyl and hydroxyalkyl;




(F)

wherein R is selected from the group consisting of aliphatic, aromatic, heterocyclic, substituted aromatic and substituted heterocyclic; and

wherein X and Y are independently selected from the group consisting of H, halogen, alkyl, alkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, hydroxy, nitro, trifluoromethyl, trifluoromethoxy and cyano;





(G)


wherein  $R_1$  is selected from the group consisting of H, halogen, alkoxy, alkyl, nitro, cyano, amino,  $CF_3$ ,  $OCF_3$ , and hydroxy;

5 wherein  $R_2$  is selected from the group consisting of H, alkyl and aminoalkyl;

wherein  $R_3$  is H or alkyl; and

wherein  $R_4$  and  $R_5$  are independently selected from the group consisting of H, alkyl, aryl, heteroaryl, substituted aryl, substituted heteroaryl, cycloalkyl, aryl, aminocycloalkyl, hydroxyalkyl and substituted aryl;

10




(H)

wherein R and  $R'$  are selected independently from the group consisting of H, methyl, alkyl, aryl and substituted aryl; and

15

wherein X, Y and Z are independently selected from the group consisting of H, halogen, alkyl, alkoxy, benzo, fused heterocyclic,  $CF_3$ ,  $OCF_3$ , CN, COOH and COOR";



(I)


wherein X and Y are selected independently from the group consisting of H, alkyl, alkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, hydroxy,  
 5 halogen,  $NO_2$ ,  $CF_3$ ,  $OCF_3$ ,  $NH_2$ ,  $NHR_3$ ,  $NR_3R_4$  and CN;

wherein Z is selected from the group consisting of O, S, NH, and N- $R'$ ;

wherein  $R'$  is selected from the group consisting of H, alkyl, aminoalkyl, and dialkylaminoalkyl;


wherein R is selected from the group consisting of H, alkyl, halogen,  
 10 alkoxy,  $CF_3$  and  $OCF_3$ ; and

$R_1$  and  $R_2$  are independently selected from the group consisting of H, alkyl, aminoalkyl, dialkylaminoalkyl, hydroxyalkyl, alkoxyalkyl, cycloalkyl, oxacycloalkyl and thiocycloalkyl;



(J)

where  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$  and  $R_6$  are selected independently from the group consisting of H, alkyl, cycloalkyl, oxacycloalkyl, thiocycloalkyl, aryl, arylalkyl, heteroaryl and heteroalkyl;




(K)

wherein  $R_1$  and  $R_2$  are independently selected from the group consisting of  
 5 H, alkyl, aryl, alkylaryl, substituted alkyl and substituted arylalkyl; and

wherein  $R_3$  is selected from the group consisting of H, alkyl, aryl, halogen,  
 $CF_3$ ,  $OCF_3$ , CN,  $NO_2$ ,  $NH_2$ , NHR, carboxy, carboxyalkyl, alkoxy, heteroaryl, fused aryl  
 and fused heteroaryl.


2. The pharmaceutical composition of Claim 1, wherein the compound is  
 10 from genus A.

3. The pharmaceutical composition of Claim 2, wherein the compound is:




4. The pharmaceutical composition of Claim 1, wherein the compound is  
 genus B.


5. The pharmaceutical composition of Claim 4, wherein the compound is  
 15 selected from the group consisting of:




II.1,




II.2,




II.3,



II.4,




II.5 and



II.6.


6. The pharmaceutical composition of Claim 1, wherein the compound is genus C.

7. The pharmaceutical composition of Claim 6, wherein the compound is:




5 8. The pharmaceutical composition of Claim 1, wherein the compound is genus E.

9. The pharmaceutical composition of Claim 8, wherein the compound is selected from the group consisting of:




V.1,




V.2,


10




V.3,




V.4,



V.5,




V.6 and




V.7.

10. The pharmaceutical composition of Claim 1, wherein the compound is genus F.


5 11. The pharmaceutical composition of Claim 10, wherein the compound is selected from the group consisting of:




VI.1,



VI.2,




VI.3,




VI.4,






VI.5,




VI.6 and




VI.7.


- 5            12.    The pharmaceutical composition of Claim 1, wherein the compound is genus G.
13.    The pharmaceutical composition of Claim 12, wherein the compound is selected from the group consisting of:




VII.1,




VII.2,




VII.3,



VII.4,




VII.5 and




VII.6.

14. The pharmaceutical composition of Claim 1, wherein the compound is  
5 genus H.

15. The pharmaceutical composition of Claim 14, wherein the compound is selected from the group consisting of:




VIII(1).1



VIII(1).2

16. The pharmaceutical composition of Claim 1, wherein the compound is genus I.

17. The pharmaceutical composition of Claim 16, wherein the compound is:



5

wherein Z is selected from the group consisting of NH, O, S and N-R';

wherein R' is selected from the group consisting of H, alkyl, aminoalkyl, and dialkylaminoalkyl;


wherein R<sub>1</sub> is selected from the group consisting of H, Cl and

10 SO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>; and

wherein R<sub>2</sub> is selected from the group consisting of H, Cl, CH<sub>3</sub>, OCH<sub>3</sub>, COOH and CF<sub>3</sub>,


18. The pharmaceutical composition of Claim 1, wherein the compound is genus J.

15 19. The pharmaceutical composition of Claim 18, wherein the compound is:




20. The pharmaceutical composition of Claim 1, wherein the compound is genus K.


21. The pharmaceutical composition of Claim 20, wherein the compound is:  
5 selected from the group consisting of:




XI.1,



XI.2,



XI.3 and



XI.4.

22. The pharmaceutical composition of any one of Claims 1-21 for use in the  
5 treatment of a disease condition associated with excess IgE.

23. The pharmaceutical composition of Claim 22, further comprising at least one additional ingredient which is active in reducing at least one symptom associated with the disease condition associated with excess IgE.


24. The pharmaceutical composition of Claim 23, wherein said at least one  
10 additional ingredient is selected from the group consisting of a short-acting  $\beta_2$ -adrenergic agonist, a long-acting  $\beta_2$ -adrenergic agonist, an antihistamine, a phosphodiesterase inhibitor, an anticholinergic agent, a corticosteroid, an inflammatory mediator release inhibitor and a leukotriene receptor antagonist.

25. Use of the pharmaceutical composition of any one of Claims 1-21 in the  
15 preparation of a medicament for treatment of a disease condition associated with excess IgE.


where X and Y are independently H, alkyl, alkoxy, alkoxyalkyl, hydroxyalkyl, aryl, benzyl, heteroaryl, hydroxy, carboxy, halogen, trifluoromethyl, trifluoromethoxy, carboxyalkyl, nitro, cyano, sulfonamide, alkylsulfonamides, amino, alkylamino, morpholine, thiomorpholine, alkylthio, sulfoxyalkyl and sulfonylalkyl, where R<sub>1</sub> and R<sub>2</sub> are independently H, alkyl, aryl, heteroaryl, carboxy, carboxyalkyl and carboxyaryl, and where R<sub>3</sub> is H, alkyl, aryl, CO-alkyl, CO-aryl or CO-heteroaryl.

The following compounds within the genus were synthesized and found to be active in suppressing IgE:


10




II.1




II.2




II.3



II.4



II.5



II.6

Compounds of formula II may be synthesized by any conventional reactions known in the art. Examples of syntheses include the following reactions:


A solution of DL- $\alpha$ -methyl-benzylamine (2.0 g, 0.017 mol) in MeOH (7.0 ml) and epichlorohydrine (1.53 g, 0.017 mol) in MeOH (7.0 ml) was stirred at room temperature for some time and then heated at about 45-50° C for 3 days. The reaction mixture was basified with 10% NaOH solution and then extracted with ether (2 x 25 ml), ether layer washed with brine, concentrated and distilled. The yield was 1.507 g, b.p. 116-120° C.

The stereochemistry variation was achieved by stirring a solution of R-(+)-1-phenylethylamine (2.0 g, 0.017 mol) in 7.0 ml of MeOH with epichlorohydrine (1.53 g, 0.017 mol) in MeOH (7.0 ml). The reaction was carried out as detailed above.

The reactants can be obtained from a commercial supplier, such as for example, Aldrich Chemical Company, catalog number 16,854-8. Modifications as suggested by formulas II(1-2) can be prepared by conventional reactions, well known in the field.

Substituted benzene rings with acylamide groups are also contemplated in accordance with the present invention, as described by generic formula III:






III

wherein X and Y are independently H, halogens, alkyl, alkoxy, alkoxyalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, trifluoromethyl, trifluoromethoxy, cyano, nitro, amino, acylamino or alkylamino, wherein R, R', R'' and R''' are independently  
 5 H, alkyl, alkoxyalkyl or dialkylaminoalkyl, and where R'' and R''' may independently also be a halogen.

A preferred variation on compound III is illustrated by the formula:



III(1)

wherein Z is H<sub>2</sub> or O; wherein X and Y are independently selected from the group consisting of H, halogens, alkyl, alkoxy, alkoxyalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, trifluoromethyl, trifluoromethoxy, cyano, nitro, amino, acylamino  
 15 and alkylamino; and wherein R<sub>1</sub> and R<sub>2</sub> may be selected independently from the group consisting of H, alkyl, alkoxyalkyl, dialkylaminoalkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl.


The following species of formula III(1) were synthesized and found to be active in suppressing IgE (see Table 1).

Table 1

	R <sub>1</sub> = R <sub>2</sub>	Z	X=Y
III.1	2,2-dimethyl-cyclopropyl	O	H
III.2	cyclopropyl	H <sub>2</sub>	H

III.3	cyclohexyl	O	H
III.4	2,2,3,3-tetramethyl-cyclopropyl	H <sub>2</sub>	H
III.5	4-methyl-benzenesulfonyl	H <sub>2</sub>	H
III.6	cyclobutyl	H <sub>2</sub>	H
III.7	2-phenyl-cyclopropyl	H <sub>2</sub>	H
III.8	1-phenyl-cyclopropyl	H <sub>2</sub>	H
III.9	2-methyl-cyclopropyl	H <sub>2</sub>	H
III.10	1-methyl-cyclopropyl	H <sub>2</sub>	H
III.11	cyclopentyl	H <sub>2</sub>	H
III.12	2,2-dimethyl-cyclopropyl	H <sub>2</sub>	Cl

The following symmetrical cyclopropyl compound within the genus was found to be particularly active in suppressing IgE:



III.1

The cyclopropyl substituted compound above was prepared in sequential reactions. First, 2,2-dimethyl-1,3-propane-ditosylate was synthesized by adding p-toluenesulfonyl chloride (1000 g, 5.25 mol) at 0° C to a solution of neopentyl glycol (218 g, 2.1 mol) in 500 ml pyridine with stirring. The mixture was stirred for 1.5 hr and then poured into 1500 ml water in a slow stream while stirring vigorously. It was stirred for an additional 1.5 hr and then filtered. The crude solid was recrystallized from acetone (2.0 L), filtered, washed with water (2 x 0.5 L), hexane (1 x 0.5 L) and dried. Snow white solid (814 g) m.p. 120-121° C.

2,2-Dimethyl-cyclopropyl nitrile was synthesized by stirring the 2,2-dimethyl-1,3-propane-ditosylate prepared above (412 g, 1.0 mol) with KCN (195.4 g, 3.0 mol) in 2.0 L of ethylene glycol with heating ( E.R. Nelson et al., JACS, 1957, p. 3467). At around 80°


C, a clear solution was formed. The desired product began to distill out at about 175° C. The distillation was continued until the temperature reached 200° C. The distillate (300 ml) formed two layers. The upper layer was separated and the lower layer was extracted with hexane (3 x 200 ml). The combined extracts were dried over Na<sub>2</sub>CO<sub>3</sub>, concentrated and re-distilled at normal pressure. The yield was 41.7 g (43.8%), b.p. 151-152° C.

2,2-Dimethyl-cyclopropyl carboxylic acid was prepared by mixing 2,2-dimethyl-cyclopropyl nitrile (41.7 g, 0.43 mol) with sodium hydroxide (44 g, 1.05 mol) in water (100 ml) and methanol (50 ml). The mixture was heated to reflux for 48 hr until a clear solution formed. Methanol was distilled off and the aqueous portion was extracted with ether (50 ml) and the aqueous layer was diluted with water (500 ml) and carefully acidified with conc. HCl. The acidified mixture was extracted with ether (5 x 300 ml), CH<sub>2</sub>Cl<sub>2</sub> (5 x 300 ml). The extract was evaporated to yield a liquid which was distilled to give 44.9 g (91.6%) of oil, b.p. 55-57° C at 0.3 mm.

2,2-Dimethyl-cyclopropyl carboxylic acid chloride was prepared by mixing 2,2-dimethyl-cyclopropyl carboxylic acid (20.0 g, 0.18 mol) in CH<sub>2</sub>Cl<sub>2</sub> (100 ml) with 45.7 g (0.36 mol, 31.4 ml) of oxalyl chloride. The mixture was stirred for 1.0 hr and then a small amount of DMF was added to ensure the completion of the reaction. The mixture was then distilled to give 17.8 g (75%) of the desired product, b.p. 84-87° C.


Compound III.1, Bis-[4-(2',2'-dimethyl-cyclopropyl carboxy-amido phenol)]-methane, was prepared by combining a solution of 4,4'-methylenedianiline (0.67 g, 3.4 mol) and diisopropyl-ethyl-amine (1.94 g, 2.61 ml, 0.019 mol) in THF (10 ml). The mixture was treated slowly with a solution of 2,2-dimethyl-cyclopropyl carboxylic acid chloride (1.0 g, 7.5 mmol) in THF (10 ml). The reaction mixture was stirred for 1.0 hr and then decomposed with water (250 ml). The precipitated solid was filtered and washed with 10% HCl (10 ml), 10% sodium hydroxide (10 ml), water and ether. The yield was 1.2 g, m.p. 207-210° C.

Related compounds within the genus can be synthesized following the above reactions. A general synthetic scheme is outlined below:



The reactants can be obtained from a commercial supplier, such as Aldrich Chemical Company, catalog number 13,245-4, and dialkylcyclopropane carboxylate is available from Sumitomo, Japan. Modifications as suggested by formulas III(1-4) can be prepared by conventional reactions, well known in the field.

A closely related genus of compounds was also found to active in down-regulating IgE levels. This class of compounds is represented by formula IV:



10

IV


where Z is H<sub>2</sub> or O, and X and Y are independently selected from the group consisting of H, halogens, alkyl, alkoxy, alkoxyalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, trifluoromethyl, trifluoromethoxy, cyano, nitro, amino, acylamino and alkylamino. R<sub>1</sub> and R<sub>2</sub> may be selected independently from the group consisting of H, alkyl, alkoxyalkyl, dialkylaminoalkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, and the like.

15

A species wherein Z = H<sub>2</sub>, X = H, Y = H and R<sub>1</sub> = R<sub>2</sub> = dimethyl-cyclopropyl was prepared from 3,6-thioxanthenediamine-10,10-dioxide (0.89 g) and 1.0 g of 2,2-dimethyl-

cyclopropyl carboxyl chloride (see above) in the presence of di-isopropyl-ethylamine (2.6 ml) in THF. The yield was 1.4 g, m.p. 273-275° C.


Another class of compounds which down-regulates IgE responses in accordance with the present invention is illustrated by the formula V:



V

wherein X and Y are independently H, halogens, alkyl, alkoxy, aryl, amino, alkylamino, cycloalkylamino, morpholine, thiomorpholine, hydroxy, cyano, nitro, carboxy, alkoxycarbonyl, trifluoromethyl or trifluoromethoxy, and R, R', R'' and R''' are independently alkyl, aryl, cycloalkyl, substituted cycloalkyl, polycycloalkyl, heteroaryl, arylalkyl, dialkylaminoalkyl, hydroxyalkyl and related groups.

The following compounds encompassed within the family defined by formula V were prepared and found to be active in suppressing IgE:



V.1



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>A61K 31/335, 31/445, 31/395, 31/165,</b> <b>31/18, 31/40, 31/42, 31/135, 31/535</b>		<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 99/61013</b>
<b>(21) International Application Number:</b> PCT/US99/11363 <b>(22) International Filing Date:</b> 21 May 1999 (21.05.99) <b>(30) Priority Data:</b> 60/086,494 22 May 1998 (22.05.98) US <b>(71) Applicant:</b> AVANIR PHARMACEUTICALS [US/US]; 9393 Towne Centre Drive #200, San Diego, CA 92121 (US). <b>(72) Inventors:</b> SIRCAR, Jagadish; Avanir Pharmaceuticals, 9393 Towne Centre Drive #200, San Diego, CA 92121 (US). RICHARDS, Mark, L.; Avanir Pharmaceuticals, 9393 Towne Centre Drive #200, San Diego, CA 92121 (US). CAMPBELL, Michael, G.; Avanir Pharmaceuticals, 9393 Towne Centre Drive #200, San Diego, CA 92121 (US). MAJOR, Michael, W.; Avanir Pharmaceuticals, 9393 Towne Centre Drive #200, San Diego, CA 92121 (US). <b>(74) Agent:</b> ALTMAN, Daniel, E.; Knobbe, Martens, Olson & Bear, LLP, 16th floor, 620 Newport Center Drive, Newport Beach, CA 92660 (US).		<b>(43) International Publication Date:</b> 2 December 1999 (02.12.99) <b>(81) Designated States:</b> AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims</i> <i>and to be republished in the event of the receipt of amendments.</i> <b>(88) Date of publication of the international search report:</b> 6 April 2000 (06.04.00)	
<b>(54) Title:</b> COMPOUNDS HAVING IgE AFFECTING PROPERTIES			
<b>(57) Abstract</b> <p>The present invention is directed to small molecule inhibitors of the IgE response to allergens which are useful in the treatment of allergy and/or asthma or any diseases where IgE is pathogenic.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakistan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 99/11363

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/335 A61K31/445 A61K31/395 A61K31/165 A61K31/18  
A61K31/40 A61K31/42 A61K31/135 A61K31/535

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 93 25517 A (CELLTECH LTD) 23 December 1993 (1993-12-23) page 2, line 9-18; claims; examples 13,15,16,19 ---	1,2,22, 25
X	WO 90 09989 A (ROTTA RESEARCH LAB) 7 September 1990 (1990-09-07) page 1 -page 2, paragraph 1 page 17, paragraph 2; claims; examples 5,7,8 page 23, last paragraph -page 24 ---	1,2,22, 25
X	EP 0 221 346 A (WARNER LAMBERT CO) 13 May 1987 (1987-05-13) whole document, especially examples 2, 25 and 48; and page 4, lines 26-47 --- -/--	1,2,22, 25

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

20 October 1999

Date of mailing of the international search report

8. 02. 00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

ORVIZ DIAZ P.



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/11363

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 497 564 A (RHONE-POULENC RORER LTD) 5 August 1992 (1992-08-05) page 2 -page 4, line 15; claims ---	1,2,22, 25
Y	EP 0 469 477 A (HOFFMANN LA ROCHE) 5 February 1992 (1992-02-05) page 2, line 1-30 page 3, line 26 page 3, line 41-47 ---	1,2, 22-25 -
Y	EP 0 232 199 A (CIRD) 12 August 1987 (1987-08-12) page 1; claims ---	1,2, 22-25
X	S. KARAG'OV: "Synthesis of N-acyl derivatives of 6-amino-1,4-benzodioxane" STN INTERNATIONAL. FILE CHEMICAL ABSTRACTS. AN=112:98470, XP002119692 abstract & FARMATSIYA, vol. 39, no. 2, 1989, pages 5-8, -----	3,22

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 11363

## Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see ADDITIONAL SHEET PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

2,3 complete 1,22-25 partially

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International Application No. PCT/ US 99 / 11363

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

The substituents in the general formulae of claim 1 are not clearly defined, contrary to Art. 6 PCT. The expression "substituted aryl", for example, encompasses an extremely large number of possibilities, which makes impossible to carry out a complete search.

Furthermore, some of the specific embodiments mentioned in the dependent claims are not covered by the formulae in claim 1. More specifically, the 2,3-dihydro-1,4-benzodioxane derivative in claim 3 is not covered by formula (A); the compounds II.3, II.5 and II.6 are not covered by formula (B); the compound V.2 is not covered by formula (C); the compound VI.3 is not covered by formula (F); none of the compounds of claim 13 is covered by formula (G); the compound VIII(1).2 is not covered by formula (H); the formula in claim 17 has two possible substituents in the bezimidazole ring (R1 and R), whereas formula (I), only has one (X), which is not one CF<sub>3</sub>, COOH or SO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>; and the compound in claim 19 is not covered by formula (J).

In view of this the search has to be limited to the general structural characteristics of the formulae in claim 1 and to the specific compounds claimed.

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/ US 99/11363

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 2, 3 (both complete) and 1, 22-25 (all partially)

Pharmaceutical compositions comprising compounds of formula  
(A)

2. Claims: 4, 5 (both complete) and 1, 22-25 (all partially)

Pharmaceutical compositions comprising compounds of formula  
(B)

3. Claims: 6, 7 (both complete) and 1, 22-25 (all partially)

Pharmaceutical compositions comprising compounds of formula  
(C)

4. Claims: 1, 22-25 (all partially)

Pharmaceutical compositions comprising compounds of formula  
(D)

5. Claims: 8, 9 (both complete) and 1, 22-25 (all partially)

Pharmaceutical compositions comprising compounds of formula  
(E)

6. Claims: 10, 11 (both complete) and 1, 22-25 (all partially)

Pharmaceutical compositions comprising compounds of formula  
(F)

# INTERNATIONAL SEARCH REPORT

International Application No. PCT/ US 99/11363

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

7. Claims: 12, 13 (both complete) and 1, 22-25 (all partially)

Pharmaceutical compositions comprising compounds of formula  
(G)

8. Claims: 14, 15 (both complete) and 1, 22-25 (all partially)

Pharmaceutical compositions comprising compounds of formula  
(H)

9. Claims: 16, 17 (both complete) and 1, 22-25 (all partially)

Pharmaceutical compositions comprising compounds of formula  
(I)

10. Claims: 18, 19 (both complete) and 1, 22-25 (all partially)

Pharmaceutical compositions comprising compounds of formula  
(J)

11. Claims: 20, 21 (both complete) and 1, 22-25 (all partially)

Pharmaceutical compositions comprising compounds of formula  
(K)

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/11363

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9325517 A	23-12-1993	AT 150447 T	15-04-1997
		AU 670949 B	08-08-1996
		AU 4347093 A	04-01-1994
		CA 2114114 A	23-12-1993
		DE 69309030 D	24-04-1997
		DE 69309030 T	25-09-1997
		DK 607373 T	13-10-1997
		EP 0607373 A	27-07-1994
		ES 2102036 T	16-07-1997
		GR 3023446 T	29-08-1997
		JP 6509820 T	02-11-1994
		US 5550137 A	27-08-1996
		HU 9500453 A	30-10-1995
		US 5340827 A	23-08-1994
WO 9009989 A	07-09-1990	IT 1232252 B	28-01-1992
		AT 106863 T	15-06-1994
		AU 627285 B	20-08-1992
		AU 5175690 A	26-09-1990
		CA 2046874 A,C	23-08-1990
		DD 294477 A	02-10-1991
		DE 69009746 D	14-07-1994
		DE 69009746 T	17-11-1994
		EP 0460083 A	11-12-1991
		ES 2055424 T	16-08-1994
		GR 90100136 A,B	28-06-1991
		HU 60464 A,B	28-09-1992
		IE 64437 B	09-08-1995
		JP 2716259 B	18-02-1998
		PT 93213 A,B	31-08-1990
		US 5232937 A	03-08-1993
EP 0221346 A	13-05-1987	US 4939133 A	03-07-1990
		AT 60575 T	15-02-1991
		AU 606848 B	21-02-1991
		AU 6279186 A	02-04-1987
		DK 463986 A	02-04-1987
		ES 2005073 A	01-03-1989
		GR 3001880 T	23-11-1992
		JP 62081359 A	14-04-1987
EP 0497564 A	05-08-1992	AT 132134 T	15-01-1996
		AT 165334 T	15-05-1998
		AU 664694 B	30-11-1995
		AU 1188192 A	27-08-1992
		AU 4565196 A	02-05-1996
		CA 2101423 A	29-07-1992
		CZ 9301528 A	13-04-1994
		DE 69207017 D	08-02-1996
		DE 69207017 T	05-09-1996
		DE 69225245 D	28-05-1998
		DK 497564 T	29-01-1996
		EP 0569414 A	18-11-1993
		EP 0669311 A	30-08-1995
		ES 2081563 T	01-03-1996
		FI 933357 A	19-08-1993
		WO 9212961 A	06-08-1992
		GR 3018544 T	31-03-1996

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/11363

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0497564 A		HU 64942 A	28-03-1994
		HU 9500720 A	28-12-1995
		IE 71647 B	26-02-1997
		IL 100788 A	10-01-1997
		JP 2664538 B	15-10-1997
		JP 6504782 T	02-06-1994
		MX 9200344 A	01-03-1993
		NO 932701 A	21-09-1993
		NZ 241427 A	26-08-1994
		PL 169994 B	30-09-1996
		SK 80993 A	08-12-1993
		US 5935978 A	10-08-1999
		US 5698711 A	16-12-1997
		ZA 9200547 A	03-05-1993
EP 0469477 A	05-02-1992	AT 128030 T	15-10-1995
		AU 651358 B	21-07-1994
		AU 8153591 A	13-02-1992
		CA 2048236 A	03-02-1992
		DE 69113162 D	26-10-1995
		DE 69113162 T	14-03-1996
		DK 469477 T	27-12-1995
		IE 70332 B	13-11-1996
		JP 4244028 A	01-09-1992
		NZ 239201 A	25-02-1994
		US 5227378 A	13-07-1993
EP 0232199 A	12-08-1987	LU 86258 A	03-09-1987
		AU 597329 B	31-05-1990
		AU 6780687 A	23-07-1987
		CA 1315201 A	30-03-1993
		CA 1337344 A	17-10-1995
		DE 3783922 A	18-03-1993
		DK 29187 A	22-07-1987
		JP 2520120 B	31-07-1996
		JP 62190154 A	20-08-1987
		NZ 218991 A	29-01-1990
		US 4927928 A	22-05-1990
		US 5212203 A	18-05-1993

THIS PAGE BLANK (USPTO)